Lilly UK

A leading innovation-driven company, Lilly makes medicines that help people live longer, healthier, more active lives. Lilly has a long heritage in discovering medicines for conditions that affect the human brain. We are applying the latest research in the fight against conditions such as Alzheimer’s, Parkinson’s, depression and schizophrenia.

Updated:
11 October 2018
Sectors:
Pharmaceutical

1. Action Plan

We have been searching for a better understanding of new treatments for Alzheimer’s disease for 30 years. Our UK-based research scientists are focused on finding the next generation of treatments for Alzheimer’s and other neurodegenerative diseases. Lilly’s vision is to make a significant contribution to humanity by improving global health. We listen carefully to understand patient needs and work with health care partners to provide meaningful benefits for the people who depend on us.

Member website

www.lilly.co.uk

2. Actions

  • Developing new medicines and diagnostics for the next generation of treatments

    Linked to Dementia Statement 5 - We have the right to know about and decide if we want to be involved in research that looks at cause, cure and care for dementia and be supported to take part.

    Lilly is committed to developing new medicines and diagnostics for the next generation of treatments to improve the lives of people with dementia. We will continue to involve people with dementia and their doctors in our clinical trial programme across the UK.

    Alzheimer’s is such a complex disease that our research must be both determined and persistent. Lilly’s research has helped shape the development of drugs being researched today. We now understand more about how Alzheimer’s disease may develop in the brain. We have research studies testing investigational drugs to see whether they may slow or stop the development of Alzheimer’s. What’s more, we are now testing new ways to see changes in the brain. This may help speed up research by helping us to find the right volunteers more quickly.

    Lilly is committed to ensuring its clinical trial programme is transparent and accessible, and to providing appropriate support to those who wish to participate.

    Status:
  • Support to dementia patients, carers and healthcare professionals through education

    Linked to Dementia Statement 4 - We have the right to be respected, and recognised as partners in care, provided with education, support, services, and training which enables us to plan and make decisions about the future.

    Lilly provides support to dementia patients, carers and healthcare professionals through education. Lilly UK has partnered with the Alzheimer’s Society for the past 8 years, including supporting the national ‘Worried About your Memory’ campaign, and supporting the National Dementia Helpline, raising awareness of symptoms and reducing the stigma associated with dementia. Lilly UK also supports Alzheimer’s Research UK. We will continue to engage with key national advocacy groups to support awareness-raising and education activities.

    We will continue to engage with key national advocacy groups to support awareness-raising and education activities.

    Status:
  • Untitled

    Linked to Dementia Statement 3 - We have the right to an early and accurate diagnosis, and to receive evidence based, appropriate, compassionate and properly funded care and treatment, from trained people who understand us and how dementia affects us. This must meet our needs, wherever we live.

    We will collaborate with leading scientists across industry and academia, through partnerships and forums, to harness scientific breakthroughs and the latest knowledge about Alzheimer’s disease. As an example, Lilly is an active participant in the European Innovative Medicines Initiative (IMI), a series of joint public/private funded programmes designed to address key healthcare problems. 

    We are currently running collaborative research studies with other organisations; we will continue to partner with academic institutions, government entities, and advocacy organizations in our search for the next generation of treatments for Alzheimer’s and other neurodegenerative diseases causing dementia.

    Status: